Breakthrough Therapy, PRIME and Sakigake: A Comparison Between Neuroscience and Oncology in Obtaining Preferred Regulatory Status - Elena Tomaselli Muensterman, Yijia Luo, Jonathon M. Parker, 2019
Sage Therapeutics' SAGE-217 fails in late-stage depression trial
Sage And Axsome Face Off In Depression (NASDAQ:AXSM) | Seeking Alpha
Sage advice: psychiatric drug development is tough | Evaluate
SEC Filing | Sage Therapeutics, Inc.
GABA-A Agent SAGE-217: A New Antidepressant? - Gateway Psychiatric
Jorge Luna on LinkedIn: So proud of my amazing team who won the Sage Therapeutics 2019 Field… | 59 comments
Sage Therapeutics surges 70% after depression drug breakthrough
Small Clinical Trials Lead To Big Results
Rx Product News: April 2023
Bipolar Depression: How do we treat it?
Sage Therapeutics Updates Pipeline to Focus on Treatment-Resistant Depression | BioSpace
Sage Therapeutics Looks to File NDA for Postpartum Depression Treatment Later This Year | BioSpace
Sage Announces Results of FDA Breakthrough Therapy Meeting – ISPE Boston
sage-10k_20181231.htm
Biogen and Sage Therapeutics in Global Collaboration – ISPE Boston
Biogen signs $1.5bn depression drug deal with Sage Therapeutics
Sage Therapeutics' Deal With Biogen Should Revive It (NASDAQ:SAGE) | Seeking Alpha
sage-10k_20191231.htm
Sage Therapeutics Could Be In For A Depressing FDA Review (NASDAQ:SAGE) | Seeking Alpha
Zuranolone, a breakthrough postpartum depression treatment, was just approved by the FDA. The fast-acting pill can improve symptoms in 3 days
Sage Therapeutics: Zuranolone's Multi-Billion Dollar Market Opportunity More Than Justifies Company Valuation (NASDAQ:SAGE) | Seeking Alpha
Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders | Business Wire
SY Investing on X: "$SAGE (-62% PM) announced pivotal Ph 3 MOUNTAIN results of SAGE-217 in MDD. Study didn't meet primary endpoint. #Fail SAGE-217 showed mean reduction of 12.6 in HAM-D total
Sage Therapeutics Announces Development Plan for Zuranolone (SAGE-217) Following Breakthrough Therapy Guidance Meeting with the U.S. Food & Drug Administration-CliniExpert
Zulresso: the world's first post-partum depression drug - Pharmaceutical Technology
Biogen signs deal with Sage to develop depression, tremor therapies
